bulaquine: structure given in first source [MeSH]
bulaquine : no description available [CHeBI]
| ID Source | ID |
|---|---|
| PubMed CID | 9831444 |
| CHEMBL ID | 3770139 |
| SCHEMBL ID | 5002047 |
| CHEBI ID | 135558 |
| MeSH ID | M0175182 |
| Synonym |
|---|
| bulaquine |
| CHEBI:135558 |
| tsq6u39q3g , |
| bulaquine [inn] |
| cdri 80-53 |
| cdri 80/53 |
| 79781-00-3 |
| compound 80/53 |
| dihydro-3-(1-((4-((6-methoxy-8-quinolyl)amino)pentyl)amino)ethylidene)-2(3h)-furanone |
| 2(3h)-furanone, dihydro-3-(1-((4-((6-methoxy-8-quinolinyl)amino)pentyl)amino)ethylidene)- |
| n'-(3-acetyl-4,5-dihydro-2-furanyl)-n(4)-(6-methoxy-8-quinolyl)-1,4-pentanediamine |
| aablaquine |
| unii-tsq6u39q3g |
| bulaquine [who-dd] |
| SCHEMBL5002047 |
| CHEMBL3770139 |
| (3z)-3-[1-[4-[(6-methoxyquinolin-8-yl)amino]pentylamino]ethylidene]oxolan-2-one |
| 3-(1-((4-((6-methoxyquinolin-8-yl)amino)pentyl)amino)ethylidene)dihydrofuran-2(3h)-one |
| Q27290262 |
| CS-0026779 |
| HY-106866 |
| Class | Description |
|---|---|
| aminoquinoline | Any member of the class of quinolines in which the quinoline skeleton is substituted by one or more amino or substituted-amino groups. |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1282060 | Cytotoxicity against HEK293T cells assessed as cell viability after 48 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8 ISSN: 1464-3391 | Novel squaramides with in vitro liver stage antiplasmodial activity. |
| AID1282058 | Antiplasmodial activity against liver stage Plasmodium berghei infected in Huh7 cells assessed as inhibition of parasite infection incubated for 1 hr prior to infection measured at 24 hrs by luciferase reporter gene assay | 2016 | Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8 ISSN: 1464-3391 | Novel squaramides with in vitro liver stage antiplasmodial activity. |
| AID1282062 | Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum W2 infected in human erythrocytes after 24 hrs by [3H]-hypoxanthine incorporation assay | 2016 | Bioorganic & medicinal chemistry, Apr-15, Volume: 24, Issue:8 ISSN: 1464-3391 | Novel squaramides with in vitro liver stage antiplasmodial activity. |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 5 (23.81) | 18.2507 |
| 2000's | 11 (52.38) | 29.6817 |
| 2010's | 2 (9.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 4 (18.18%) | 5.53% |
| Reviews | 1 (4.55%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 17 (77.27%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| primaquine | aminoquinoline; aromatic ether; N-substituted diamine | antimalarial | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| chloroquine | aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound | anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug | 2000 | 2018 | 17.2 | medium | 1 | 0 | 1 | 2 | 1 | 0 | |
| primaquine | aminoquinoline; aromatic ether; N-substituted diamine | antimalarial | 1989 | 2018 | 24.2 | high | 4 | 3 | 6 | 10 | 1 | 0 | |
| pyrimethamine | aminopyrimidine; monochlorobenzenes | antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| sulfadoxine | pyrimidines; sulfonamide | antibacterial drug; antimalarial | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| artemisinin | organic peroxide; sesquiterpene lactone | antimalarial; plant metabolite | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |
| sesquiterpenes | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 | |||
| quinine | cinchona alkaloid | antimalarial; muscle relaxant; non-narcotic analgesic | 2004 | 2018 | 14.7 | low | 2 | 0 | 0 | 2 | 1 | 0 | |
| mefloquine | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Acute Disease | 0 | 2004 | 2004 | 20.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Adverse Drug Event | 0 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Body Weight | 0 | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 | |
| Deficiency of Glucose-6-Phosphate Dehydrogenase | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Disease Models, Animal | 0 | 2000 | 2005 | 21.5 | low | 0 | 0 | 1 | 1 | 0 | 0 | |
| Drug-Related Side Effects and Adverse Reactions | 0 | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 | |
| Glucosephosphate Dehydrogenase Deficiency | 0 | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 | |
| Infections, Plasmodium | 0 | 1989 | 2016 | 24.0 | medium | 0 | 1 | 1 | 1 | 1 | 0 | |
| Malaria | 0 | 1989 | 2016 | 24.0 | medium | 0 | 1 | 1 | 1 | 1 | 0 | |
| Malaria, Falciparum | 0 | 2004 | 2018 | 14.7 | low | 2 | 0 | 0 | 2 | 1 | 0 | |
| Malaria, Vivax | 0 | 2001 | 2006 | 20.5 | low | 2 | 0 | 0 | 2 | 0 | 0 | |
| Methemoglobinemia | 0 | 1989 | 2000 | 29.5 | low | 0 | 1 | 1 | 0 | 0 | 0 | |
| Parasitemia | 0 | 2004 | 2006 | 19.0 | low | 2 | 0 | 0 | 2 | 0 | 0 | |
| Plasmodium falciparum Malaria | 0 | 2004 | 2018 | 14.7 | low | 2 | 0 | 0 | 2 | 1 | 0 | |
| Plasmodium vivax Malaria | 0 | 2001 | 2006 | 20.5 | low | 2 | 0 | 0 | 2 | 0 | 0 | |
| Sensitivity and Specificity | 0 | 1998 | 2003 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Article | Year |
|---|---|
| Safety and tolerability of elubaquine (bulaquine, CDRI 80/53) for treatment of Plasmidium vivax malaria in Thailand. The Korean journal of parasitology, , Volume: 44, Issue:3 | 2006 |
| A randomized, parallel study of the safety and efficacy of 45 mg primaquine versus 75 mg bulaquine as gametocytocidal agents in adults with blood schizonticide-responsive uncomplicated falciparum malaria [ISCRTN50134587]. BMC infectious diseases, , Feb-01, Volume: 6 | 2006 |
| A simple and rapid evaluation of methemoglobin toxicity of 8-aminoquinolines and related compounds. Ecotoxicology and environmental safety, , Volume: 45, Issue:3 | 2000 |
| Article | Year |
|---|---|
| In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences. Biopharmaceutics & drug disposition, , Volume: 28, Issue:5 | 2007 |
| Analysis and pharmacokinetics of bulaquine and its major metabolite primaquine in rabbits using an LC-UV method--a pilot study. Journal of pharmaceutical and biomedical analysis, , Apr-24, Volume: 32, Issue:1 | 2003 |
| A rapid and sensitive high performance liquid chromatographic assay of the new antimalarial compound 80/53 in serum with a novel sample clean-up method and its pharmacokinetics in rabbits. Journal of pharmaceutical and biomedical analysis, , Volume: 17, Issue:4-5 | 1998 |
| Article | Year |
|---|---|
| In Vitro and In Vivo pharmacokinetic studies of bulaquine (analogue of primaquine), a novel antirelapse antimalarial, in rat, rabbit and monkey--highlighting species similarities and differences. Biopharmaceutics & drug disposition, , Volume: 28, Issue:5 | 2007 |